Full-Time
AI / ML Principal Engineer
Posted on 5/23/2026
Stryker
10,001+ employees
Manufactures orthopedic and surgical medical devices
No salary listed
Bengaluru, Karnataka, India
Hybrid
 Software Engineering (1) |
|---|
- Bachelor’s or Master’s degree in Computer Science, Engineering, AI, or related field.
- 12+ years of experience in software engineering with substantial experience in AI/ML systems.
- 6+ years of experience designing and deploying production-grade AI/ML architectures.
- Deep expertise in speech technologies (automatic speech recognition and text-to-speech), natural language processing, and modern large language model systems.
- Strong proficiency in Python and AI frameworks (PyTorch, TensorFlow, etc.).
- Proven experience architecting AI workloads on Microsoft Azure.
- Strong background in distributed systems, backend architecture, APIs, and data pipelines.
- Demonstrated experience leading architecture decisions across multiple teams.
- Define and own the end-to-end AI/ML architecture for speech, voice intelligence, and GenAI platforms.
- Establish scalable patterns for real-time speech processing (low-latency automatic speech recognition, text-to-speech, streaming pipelines).
- Architect retrieval-augmented generation-based systems, large language model orchestration layers, semantic search, and conversational AI frameworks.
- Drive design decisions across model hosting, inference optimization, observability, reliability, and cost efficiency.
- Define evaluation frameworks for model quality, accuracy, bias, hallucination control, and safety.
- Design enterprise-grade, cloud-native AI systems on Microsoft Azure.
- Lead architectural decisions for model lifecycle management, multi-model orchestration, feature stores and vector databases, high-throughput inference pipelines, and secure data handling in healthcare environments.
- Ensure systems meet performance service level agreements (latency, throughput, error rates) and compliance requirements.
- Drive multi-region scalability and disaster recovery strategy for AI workloads.
- Architect solutions for real-time speech-to-text and text-to-speech, domain-adapted automatic speech recognition models, intent recognition and entity extraction, conversational AI assistants, summarization and contextual intelligence.
- Define strategies for handling accents, noisy environments, and healthcare-specific terminology.
- Guide model fine-tuning and adaptation for clinical communication use cases.
- Lead adoption of large language model-based architectures including retrieval-augmented generation pipelines, prompt orchestration frameworks, guardrails and safety layers, evaluation and monitoring systems.
- Define best practices for prompt engineering, model benchmarking, and production hardening.
- Drive responsible AI practices including governance, auditability, and compliance.
- Provide architectural guidance across multiple pods and teams.
- Review and approve technical designs impacting AI systems.
- Mentor senior engineers and elevate AI engineering maturity across the organization.
- Partner with Product, User Experience, Security, DevOps, and Platform teams to align AI capabilities with business strategy.
- Participate in customer and executive discussions to translate technical vision into business value.
- Drive innovation initiatives, patents, and strategic technical investments.
- Hands-on experience with Azure OpenAI, Azure ML, and enterprise LLM deployments.
- Experience designing retrieval-augmented generation architectures with vector databases and semantic search.
- Expertise in model evaluation frameworks, machine learning observability, and performance tuning.
- Experience adapting or fine-tuning speech models for domain-specific use cases.
- Familiarity with LangChain, MLflow, prompt evaluation tooling, and model governance frameworks.
- Deep experience with Azure OpenAI, Azure ML, Azure AI Search, Azure Functions / Container Apps, Kubernetes-based model serving.
- Experience with continuous integration and continuous deployment for machine learning systems (MLOps best practices).
- Exposure to Amazon Web Services or Google Cloud Platform AI services is a plus.
- Experience building secure, compliant systems in regulated environments.
- Understanding of protected health information handling, data privacy, and enterprise-grade security controls.
Stryker designs, manufactures, and sells medical devices across multiple areas, including surgical equipment, neurotechnology, and orthopedic implants, to hospitals and clinics worldwide. Its products are developed through engineering and clinical input, then manufactured and distributed to healthcare providers who use them during procedures to improve patient care and surgical efficiency. Stryker differentiates itself from competitors with a broad, integrated portfolio, a global sales and service network, and a strong emphasis on quality and ongoing product development to support safer, more efficient procedures. The company’s goal is to advance patient outcomes by delivering reliable, effective medical devices that expand access to care globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
Kalamazoo, Michigan
Founded
1941
Simplify's Take
What believers are saying
- Robotic surgery leadership drives double-digit sales growth through 2025.
- India Trident II launch targets aging population's rising hip surgeries.
- Peripheral vascular expansion via IVL meets growing arterial disease demand.
What critics are saying
- Handala cyberattack on March 11 delays ortho supply chain 3-6 months.
- Zimmer Biomet Persona IQ erodes ortho share with real-time analytics.
- J&J Velys captures 25% more knee procedures from Mako in 6-12 months.
What makes Stryker unique
- Stryker holds 39.1% US market share in orthopedic product manufacturing.
- Trident II Acetabular System integrates Mako SmartRobotics for hip replacements.
- Amplitude Vascular Systems acquisition adds CO₂ IVL for peripheral arteries.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Stryker who can refer or advise you
Benefits
Medical & prescription plans
Supplemental health benefits
Flexible Spending accounts
Employee Assistance Program
Short-term & long-term disability
Tuition reimbursement
401(k) plan
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Distalmotion targets ASC gynecology programs with new FDA filing Distalmotion has submitted a 510(k) application to the FDA seeking to expand the label of its Dexter robotic surgery system into additional gynecological indications, the company announced April 1. The filing covers sacrocolpopexy, sacrocervicopexy and endometriosis resection. Sacrocolpopexy and sacrocervicopexy are procedures used to treat pelvic…
Stryker Corporation has signed a definitive agreement to acquire Amplitude Vascular Systems, a Boston-based medical technology company developing next-generation intravascular lithotripsy technology for treating calcified peripheral arterial disease. Financial terms were not disclosed. AVS's technology uses pulsed CO₂-generated pressure waves delivered through a balloon catheter to fracture calcium deposits. The platform aims to enhance catheter deliverability, treatment speed and therapy efficiency. The acquisition will strengthen Stryker's peripheral vascular portfolio and expand its presence in arterial disease treatment. Stryker CEO Kevin Lobo said the deal advances the company's vision to build a comprehensive peripheral vascular platform addressing significant clinical needs. IVL technology is experiencing strong growth as physicians increasingly adopt it for calcium modification in complex cardiovascular procedures. The transaction remains subject to customary closing conditions.
Stryker has raised $120 million in a Series C round led by Ribbit Capital, valuing the medical technology company at $1.45 billion. The funding comes despite shares declining 7.6% over the past six months, outperforming the industry's 19.7% drop. The company delivered 11% organic sales growth in Q4 2025 and 10.3% for the full year, marking its fourth consecutive year of double-digit growth. Performance was broad-based across its Orthopaedics, MedSurg and Neurotechnology segments, driven by strong procedural volumes and favourable demographics. Stryker achieved over 100 basis points of operating margin expansion for the second consecutive year despite tariff pressures. The company enters 2026 with a robust capital equipment backlog, though rising interest costs and tariffs present near-term challenges. Analysts maintain a Hold rating on the stock.
Stryker shares fell 9% to $339 following a destructive cyberattack by Iranian-linked group Handala that wiped over 200,000 systems and disrupted manufacturing and shipping operations across 56,000 employees in 61 countries. The medical technology company confirmed disruptions to order processing but stated there was no indication of ransomware. Unlike typical ransomware attacks, this wiper attack permanently deleted data rather than holding it for ransom, complicating recovery efforts. The incident threatens Stryker's 8% to 9.5% organic growth guidance for 2026 if operations fail to normalise quickly. Stryker generated $25 billion in revenue in 2025 with $4.283 billion in free cash flow and holds $4 billion in cash. Analysts maintain a consensus price target of $424.89 with 22 buy ratings and no sell ratings among 30 covering analysts.
Stryker reported Q4 revenues of $7.17 billion, up 11.4% year-over-year and exceeding analyst expectations by 0.8%. The medical device manufacturer, which impacts over 150 million patients annually through its orthopaedics, surgical tools, neurotechnology and patient care solutions, delivered what CEO Kevin Lobo called "an outstanding finish to 2025". The company achieved double-digit sales and adjusted earnings per share growth for both the quarter and full year, whilst expanding adjusted operating margin by at least 100 basis points for the second consecutive year. Across the medical devices and supplies sector, the six diversified stocks tracked reported mixed Q4 results. As a group, revenues beat consensus estimates by 1.9%, though share prices have declined an average of 5.1% since the latest earnings announcements.